Development of New Benzo[b]Thiophene-2-Carboxamide Derivatives as Advanced Glycation End-Products Receptor (RAGE) Antagonists.

Lisa Bonin, Matthieu Hedouin, Christophe Furman, Ophélie Not, Steve Lancel, Mona Bensalah, Gael Coadou, Eric Boulanger, Sergiu Shova, Hassan Oulyadi, Alina Ghinet

Junia, Health and Environment, Laboratory of Sustainable Chemistry and Health, F-59000, Lille, France. · pubmed

Paper

Abstract

The activation of the receptor for advanced glycation end-products (RAGE) induces a chronic, low-noise inflammation responsible for the aging process, known as inflammaging. Associated with numerous pathologies such as Alzheimer's, insulin-resistant diabetes, cardiovascular diseases, and certain cancers, RAGE has become an interesting therapeutic target in the context of aging well. To this end, we identified new benzo[b]thiophene-2-carboxamide derivatives as potential RAGE ligands. Herein, we developed an alternative approach to easily synthesize benzo[b]thiophene-2-carboxamide analogs from 5-arylidene-2,4-thiazolidinedione intermediates based on the Ullmann-Goldberg coupling conditions. In light of LCMS, NMR, X-ray, and DFT studies, a mechanism for this reaction was proposed. This novel strategy enabled us to synthesize analogs whose best molecule 3t', with an IC

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims to develop new benzo[b]thiophene-2-carboxamide derivatives as RAGE antagonists to potentially mitigate chronic inflammation associated with aging. The focus on RAGE as a therapeutic target for addressing the underlying mechanisms of inflammaging aligns with longevity research.

Author of this paper? Send a correction.